DUBLIN, Ohio, June 10, 2014 — Cardinal Health today announced the 2 millionth shipment of the Mynx Vascular Closure Device (VCD). The Mynx Product Family of vascular closure devices combines the reliability of an easy-to-use deployment system with the security of mechanical closure and the safety of an extravascular sealant that enables physicians to seal an arteriotomy securely without leaving anything permanently behind in the artery.
“There are several vascular closure devices on the market, but most of them leave material behind, either inside the femoral artery, like a plug, or material in the arterial wall, like a suture or clip, which limits their use in certain situations,” said Dr. Najam Wasty, director of Invasive Cardiovascular Laboratory and director of Interventional Cardiology Fellowship Training Program at a major teaching institution. “The major advantage of the Mynx VCD is that it is extravascular. In other words, it does not leave any materials permanently inside the artery or in the wall of the artery. Many physicians find this feature attractive since it allows safe use of the Mynx VCD in most situations.”
The first Mynx Vascular Closure Device received FDA approval in May 2007. The leading extravascular closure device in the United States, the Mynx Product Family includes the new Mynx Ace Vascular Closure Device, launched in 2013 in the U.S., and the MynxGrip Vascular Closure Device, launched in 2012. Mynx devices use proprietary Grip Technology™, a major advancement in sealant technology. Grip Technology employs an extravascular sealant that actively adheres to the artery for safe and secure mechanical closure and dissolves within 30 days, leaving nothing permanently behind in the healed artery.
“We are gratified to see that Mynx has generated such a strong response,” said Shaden Marzouk, vice president, Clinical Affairs at Cardinal Health. “We believe the success of Mynx in the marketplace is a result of its unique combination of innovative design, outstanding outcomes and cost effectiveness.”
Cardinal Health completed its acquisition of AccessClosure in May.
The Mynx product family is clinically proven and has been featured in several peer-reviewed articles. More articles and information can be found on AccessClosure’s website, www.accessclosure.com.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $101 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products and services to more than 100,000 locations each day and is also the industry-leading direct-to-home medical supplies distributor. The company is a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company operates the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #22 on the Fortune 500, Cardinal Health employs 33,000 people worldwide. More information about the company may be found at www.cardinalhealth.com and @CardinalHealth on Twitter.
